Linda Pilgaard

Linda Pilgaard

Auto-generated profile, based on publicly available information

Linda Pilgaard

Laboratory of Cancer Biology, Biomedicine, Institute of Medicine and Health Technology, Fredrik Bajers Vej 3B, 1.216, Aalborg University, 9220 Aalborg East, Denmark

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2013 in Journal of Drug Delivery
Verified
Journal Article
Open access
PDF file
JMJoachim Høg Mortensen
Joachim Høg Mortensen
MTMaria Thastrup
Maria Thastrup
LPLinda Pilgaard
Linda Pilgaard
RARalf Agger
Ralf Agger
MDMeg Duroux
Meg Duroux
TMTorben Moos
Torben Moos
Therapeutic advances do not circumvent the devastating fact that the survival rate in glioblastoma multiforme (GBM) is less than 5%. Nanoparticles consisting of liposome-based therapeutics are provided against a variety of cancer types including GBM, but available liposomal formulations are provided without targeting moieties, which increases the dosing demands to reach therapeutic concentrations with risks of side effects. We prepared PEGylated immunoliposomes (ILs) conjugated with anti-human epidermal growth factor receptor (EGFR) antibodies Cetuximab (α-hEGFR-ILs). The affinity of the α-hEGFR-ILs for the EGF receptor was evaluated in vitro using U87 mg and U251 mg cells and in vivo using an intracranial U87 mg xenograft model. The xenograft model was additionally analyzed with respect to permeability to endogenous albumin, tumor size, and vascularization. The in vitro studies revealed significantly higher binding of α-hEGFR-ILs when compared with liposomes conjugated with isotypic nonimmune immunoglobulin. The uptake and internalization of the α-hEGFR-ILs by U87 mg cells were further confirmed by 3D deconvolution analyses. In vivo, the α-hEGFR-ILs accumulated to a higher extent inside the tumor when compared to nonimmune liposomes. The data show that α-hEGFR-ILs significantly enhance the uptake and accumulation of liposomes in this experimental model of GBM suggestive of improved specific nanoparticle-based delivery.

1 February 2009 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
HJHe Johnsen
He Johnsen
ASA Schmitz
A Schmitz
KFKb Fogd
Kb Fogd
HAH Andersen
H Andersen
KVKarin Vanderkerken
Karin Vanderkerken
LPL Pilgaard
L Pilgaard